The company has reported the first phase 3 results in hand for gadoquatrane, which reduces the dose of gadolinium delivered ...

Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials.The QUANTI studies examined gadoquatrane at a ...

Long COVID is more than just lingering symptoms—it may have a hidden biological basis that standard medical tests fail to ...

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of its next generation MRI contrast agent development program in ...

A new study utilizing PREFUL MRI has identified significant lung abnormalities in children suffering from long Covid without ...

Free-breathing phase-resolved functional lung (PREFUL) magnetic resonance imaging (MRI)-derived parameters can ident ...

Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The ...

Students in the fields of engineering, biology, and neuroscience who are interested in aging in depth knowledge about Magnetic resonance imaging (MRI) which is a diagnostic ... signal-to-noise, ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

Bayer presents positive results from phase III study QUANTI CNS of gadoquatrane at ECR 2025: Berlin Thursday, February 27, 2025, 14:00 Hrs [IST] Bayer, a global leader in radiolog ...

NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III ... Ferumoxtran is an MRI Contrast Agent that may ...